Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

41.15 -0.54 (-1.30%)
Streaming Delayed Price Updated: 9:37 AM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
This Biotech Looks Good With Increased M&A activity ↗
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for... 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Exelixis: Q1 Earnings Insights ↗
Exelixis (NASDAQ:EXEL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by... 
Via Benzinga
News headline image
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 17, 2022 ↗
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
Via Benzinga
News headline image
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer ↗
 
Via Benzinga
News headline image
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
From Exelixis, Inc.
Via Business Wire
News headline image
7 Top-Rated Biotech Stocks to Buy for Q2 ↗
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. 
Via InvestorPlace
News headline image
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
From Exelixis, Inc.
Via Business Wire
News headline image
Friday Markets News ↗
Methane leaks in the Permian Basin are 6 times higher than estimates. 
Via Talk Markets
News headline image
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer ↗
Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have  
Via Benzinga
News headline image
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Flood Helping Ukraine ↗
Emerging markets are gaining as mature markets look risky. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
News headline image
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Futures Flat As Traders Brace For Op-Ex Volatility, More Ukraine Headlines ↗
In the latest geopolitical developments Russian Foreign Minister Sergei Lavrov agreed to meet US Secretary of State Antony Blinken for talks in Europe next week; German Chancellor Olaf Scholz will host... 
Via Talk Markets
News headline image
Exelixis: Q4 Earnings Insights ↗
Exelixis (NASDAQ:EXEL) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings... 
Via Benzinga
News headline image
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Earnings Preview For Exelixis ↗
Exelixis (NASDAQ:EXEL) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will... 
Via Benzinga
News headline image
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial ↗
Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (... 
Via Benzinga
News headline image
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
From Exelixis, Inc.
Via Business Wire
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.